

Informazione	Data/Ora Ricezione	
Regolamentata n.	29 Aprile 2015 22:22:19	MTA
0696-48-2015		

Societa' : CTI BIOPHARMA

Identificativo : 57365

Informazione

Regolamentata

Nome utilizzatore : CELLN01 - Villa

Tipologia : IRAG 09

Data/Ora Ricezione : 29 Aprile 2015 22:22:19

Data/Ora Inizio : 29 Aprile 2015 22:37:19

Diffusione presunta

Oggetto : CTI BioPharma Corp.: Annual Meeting

postponed to a date to be determined

Testo del comunicato

Vedi allegato.



CTI BioPharma postpones Annual Meeting to a date to be determined

April 29, 2015 Seattle — CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced that its Board of Directors has voted to postpone the Annual Meeting of Shareholders from June 30, 2015 to a date to be determined due to administrative and scheduling reasons.

Therefore, the preliminary notice of call of the Annual Meeting of Shareholders expected to be held on June 30, 2015, published on the Company's website (http://www.ctibiopharma.com/assemblea-degli-azionisti) and the daily newspaper "Italia Oggi", is revoked.

The new date and record date for the Annual Meeting of Shareholders, as well as the relevant agenda (that the Board of Directors could amend as compared to the original one), will be communicated through the publication of a new preliminary notice of the call.

About CTI BioPharma Corp.

CTI BioPharma Corp. (NASDAQ and MTA: CTIC) is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers that offer a unique benefit to patients and healthcare providers. CTI BioPharma has a commercial presence in Europe and a late-stage development pipeline, including pacritinib, CTI BioPharma's lead product candidate, which is currently being studied in a Phase 3 program for the treatment of patients with myelofibrosis. CTI BioPharma is headquartered in Seattle, Washington, with offices in London and Milan under the name CTI Life Sciences Limited. For additional information and to sign up for email alerts and get RSS feeds, please visit www.ctibiopharma.com.

Source: CTI BioPharma Corp.

###

Contacts:

Monique Greer +1 206-272-4343 mgreer@ctibiopharma.com

Ed Bell +1 206-282-7100 ebell@ctibiopharma.com In Europe: CTI Life Sciences Limited, Milan Branch

Laura Villa +39 02 94751572 lvilla@cti-lifesciences.com

Fine Comunicato n.	.0696-48
--------------------	----------

Numero di Pagine: 3